WO2004012681A3 - Cancer vaccines containing epitopes of oncofetal antigen - Google Patents

Cancer vaccines containing epitopes of oncofetal antigen Download PDF

Info

Publication number
WO2004012681A3
WO2004012681A3 PCT/US2003/024518 US0324518W WO2004012681A3 WO 2004012681 A3 WO2004012681 A3 WO 2004012681A3 US 0324518 W US0324518 W US 0324518W WO 2004012681 A3 WO2004012681 A3 WO 2004012681A3
Authority
WO
WIPO (PCT)
Prior art keywords
oncofetal antigen
cancer vaccines
vaccines containing
containing epitopes
fragments
Prior art date
Application number
PCT/US2003/024518
Other languages
French (fr)
Other versions
WO2004012681A2 (en
Inventor
Joseph H Coggin Jr
James W Rohrer
Adel L Barsoum
Original Assignee
South Alabama Medical Sciences
Joseph H Coggin Jr
James W Rohrer
Adel L Barsoum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South Alabama Medical Sciences, Joseph H Coggin Jr, James W Rohrer, Adel L Barsoum filed Critical South Alabama Medical Sciences
Priority to CA2492938A priority Critical patent/CA2492938C/en
Priority to ES03767221.9T priority patent/ES2565578T3/en
Priority to AU2003258081A priority patent/AU2003258081A1/en
Priority to EP03767221.9A priority patent/EP1538900B1/en
Priority to US10/523,277 priority patent/US7718762B2/en
Publication of WO2004012681A2 publication Critical patent/WO2004012681A2/en
Publication of WO2004012681A3 publication Critical patent/WO2004012681A3/en
Priority to US12/462,514 priority patent/US8709405B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Abstract

Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. The fragments may be formulated into compositions for potentiating T cell-mediated response in mammalian cancer patients. They also have therapeutic uses in vitro.
PCT/US2003/024518 2002-08-02 2003-08-04 Cancer vaccines containing epitopes of oncofetal antigen WO2004012681A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2492938A CA2492938C (en) 2002-08-02 2003-08-04 Cancer vaccines containing epitopes of oncofetal antigen
ES03767221.9T ES2565578T3 (en) 2002-08-02 2003-08-04 Cancer vaccines containing oncofetal antigen epitopes
AU2003258081A AU2003258081A1 (en) 2002-08-02 2003-08-04 Cancer vaccines containing epitopes of oncofetal antigen
EP03767221.9A EP1538900B1 (en) 2002-08-02 2003-08-04 Cancer vaccines containing epitopes of oncofetal antigen
US10/523,277 US7718762B2 (en) 2002-08-02 2003-08-04 Cancer vaccines containing epitopes of oncofetal antigen
US12/462,514 US8709405B2 (en) 2002-08-02 2009-08-05 Cancer vaccines containing epitopes of oncofetal antigen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40085102P 2002-08-02 2002-08-02
US60/400,851 2002-08-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10523277 A-371-Of-International 2003-08-04
US12/462,514 Continuation US8709405B2 (en) 2002-08-02 2009-08-05 Cancer vaccines containing epitopes of oncofetal antigen

Publications (2)

Publication Number Publication Date
WO2004012681A2 WO2004012681A2 (en) 2004-02-12
WO2004012681A3 true WO2004012681A3 (en) 2004-11-11

Family

ID=31495892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024518 WO2004012681A2 (en) 2002-08-02 2003-08-04 Cancer vaccines containing epitopes of oncofetal antigen

Country Status (6)

Country Link
US (2) US7718762B2 (en)
EP (1) EP1538900B1 (en)
AU (1) AU2003258081A1 (en)
CA (1) CA2492938C (en)
ES (1) ES2565578T3 (en)
WO (1) WO2004012681A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286312A1 (en) * 2002-06-12 2008-11-20 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
US20060003315A1 (en) * 2002-06-12 2006-01-05 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulin covalently linked to mhc class 1 peptide epitopes
ES2282355T3 (en) 2002-10-11 2007-10-16 Sentoclone Ab CANCER IMMUNOTHERAPY.
US20080206270A1 (en) * 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
EP1717245B1 (en) * 2005-04-26 2011-06-08 Immatics Biotechnologies GmbH T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
EP1966369B1 (en) 2005-12-21 2010-10-06 Sentoclone AB Method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
US8211424B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating malignant melanoma
US8211425B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating disseminated cancer
US8101173B2 (en) 2005-12-21 2012-01-24 Sentoclone International Ab Method for treating urinary bladder cancer
EP1981533A1 (en) * 2006-02-06 2008-10-22 Medizinische Universität Wien Vaccine and antigen mimotopes against cancerous diseases associated with the carcinoembryonic antigen cea
CA2597840A1 (en) 2006-09-01 2008-03-01 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Methods and compositions for the treatment and prevention of cancer
WO2010111669A1 (en) * 2009-03-26 2010-09-30 Quantum Immunologics, Inc. Oncofetal antigen/immature laminin receptor peptides for the sensitization of dendritic cells for cancer therapy
WO2010111671A1 (en) * 2009-03-26 2010-09-30 Quantum Immunologics, Inc. Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
US20130052211A1 (en) * 2009-07-09 2013-02-28 South Alabama Medical Science Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
EP2330122A1 (en) * 2009-12-02 2011-06-08 Asklepios Kliniken Hamburg Gmbh OFA/iLRP derived modified peptide
EP3351641A1 (en) 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
GB201519557D0 (en) * 2015-11-05 2015-12-23 Univ Witwatersrand Jhb Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
WO2017083618A1 (en) 2015-11-13 2017-05-18 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335174B1 (en) * 1996-04-05 2002-01-01 South Alabama Medical Science Foundation Oncofetal antigen specific t-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
WO1998053048A1 (en) * 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
DE10041515A1 (en) 2000-08-24 2002-03-14 Gerold Schuler Process for the production of ready-to-use, antigen-loaded or unloaded, cryopreserved mature dendritic cells
US7118753B2 (en) * 2002-02-08 2006-10-10 Anawrahta Biotech Co., Ltd. Enhancing cell-based immunotherapy
AU2003249382A1 (en) 2002-06-26 2004-01-19 Pharmablood Inc. A method and composition to elicit an effective autologous antitumoral immune response in a patient
EP1717245B1 (en) 2005-04-26 2011-06-08 Immatics Biotechnologies GmbH T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARMSTRONG A:C. ET AL: "Vaccines in Oncology: Background and clinical potential", BRITISH JOURNAL OF RADIOLOGY, vol. 74, no. 887, November 2001 (2001-11-01), pages 991 - 1002, XP002981880 *
COGGIN JR ET AL: "37 Kilodalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers", ANTICANCER RES., vol. 19, no. 6C, November 1999 (1999-11-01) - December 1999 (1999-12-01), pages 5535 - 5542, XP002981891 *
NUKAYA I. ET AL: "Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte", INT. J. CANCER, vol. 80, no. 1, January 1999 (1999-01-01), pages 92 - 97, XP002981879 *

Also Published As

Publication number Publication date
CA2492938C (en) 2012-05-22
CA2492938A1 (en) 2004-02-12
EP1538900A2 (en) 2005-06-15
US8709405B2 (en) 2014-04-29
AU2003258081A8 (en) 2004-02-23
WO2004012681A2 (en) 2004-02-12
US20100183643A1 (en) 2010-07-22
US20060165709A1 (en) 2006-07-27
ES2565578T3 (en) 2016-04-05
US7718762B2 (en) 2010-05-18
EP1538900A4 (en) 2008-09-24
EP1538900B1 (en) 2016-01-06
AU2003258081A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
WO2004012681A3 (en) Cancer vaccines containing epitopes of oncofetal antigen
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO2005081854A3 (en) Egf receptor epitope peptides and uses thereof
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
IN2012DN00313A (en)
WO2007039192A3 (en) Compositions and methods for treating tumors presenting survivin antigens
WO2004022709A3 (en) Epitope sequences
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
EP2457928A3 (en) Monoclonal human tumor-specific antibody
TR200100936T2 (en) Therapeutic vaccination
IL214325A (en) Anti-cmet antibody, composition comprising it and use thereof
WO2006037421A3 (en) Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
WO2006002102A3 (en) Spirocyclic compounds useful as modulators of nuclear hormone receptor function
WO2001085203A3 (en) Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
UA97092C2 (en) T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
EP1556513A4 (en) Compositions and methods for treating human papillomavirus-mediated disease
MXPA05010575A (en) Peptabody for cancer treatment.
Smorlesi et al. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma
WO2004026238A3 (en) Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
WO2001092306A3 (en) Therapeutic compounds for ovarian cancer
WO2001068677A3 (en) Derivatives of breast canacer antigen her-2 for therapeutical use
OÈsterborg et al. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2492938

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003767221

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003767221

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006165709

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10523277

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10523277

Country of ref document: US